| |
High/Bio Tech
Biomedical Industry
As home to pharmaceutical and biomedical leaders
such as Pfizer, Wyeth-Ayerst, and Forest
Laboratories, New York State has committed to and
realized considerable biomedical industry growth.
This is due, in part, to the significant commitment
made by New York State to expand businesses and
create new high technology and biotechnology
opportunities —reaching $1.2 billion in 2005. This
includes $225 million under the Gen*NY*sis Program
(Generating Employment through New York State
Science)--a program focused on all stages of the
life sciences research and development process, from
basic research to applied research to final product,
encouraging collaboration between public and private
research institutions with emerging as well as
established companies.
New York’s leading research facilities are home
to top international medical researchers, and with
the State’s visionary strategy of leveraging both
public and private sector funds, has set the stage
for future growth in the field. This commitment
delivers strong economic benefits to New York by
expanding job growth and identifying new business
opportunities for established and emerging
businesses.
The following resources contribute to the State’s
extraordinary life sciences infrastructure:
- Center of Excellence in Bioinformatics and
Life Sciences. New York’s Center of Excellence
in Bioinformatics and Life Sciences at SUNY
Buffalo seeks to discover target molecules for
use in molecular diagnostics and therapeutic
development. The collaboration includes the
State University of New York at Buffalo, the New
York Health Department’s Roswell Park Cancer
Institute, the Hauptman Woodward Medical
Research Institute and several private life
science firms.
- The Center in Biomolecular Diagnostics and
Therapeutics at
SUNY Stony Brook conducts research and
technology development in the areas of
functional genomics instrumentation, gene
discovery, drug design and delivery, and smart
micro- and nano-based biomaterials and
biosensors. Chief partners are Brookhaven
National Laboratory and Cold Spring Harbor
Laboratory.
- The Center of Disease Modeling and Therapy
Discovery at
SUNY Buffalo conducts research to develop
new therapies to prevent and treat diseases.
Chief partners are Roswell Park Cancer
Institute, Hauptman-Woodward Medical Research
Institute, Kaleida Health, SUNY Albany, and IBM.
-
The New York Structural Biology Center at
City University of New York represents a unique
facility that provides New York’s
internationally leading researchers with
state-of-the-art equipment for research
collaboration. Chief partners are Albert
Einstein College of Medicine, Columbia
University, Memorial Sloan-Kettering Cancer
Center, Mount Sinai School of Medicine, New York
University, the Rockefeller University,
Wadsworth Center Laboratory, and Weill Medical
College of Cornell University.
- The Genomic Technologies & Information
Sciences Center at
Cornell University focuses on technologies
for identifying genes and gene functions. It
plans to establish a leading bioinformatics and
computational biology research center that
applies genomic theories and technologies to
solve problems and support State projects in
agriculture, biosciences, bioengineering and
veterinary medicine.
- The Center for Pharmacogenomics at
Albany Medical College identifies candidate
genes for disease susceptibility, as well as
adverse reactions to chemicals and drugs.
Findings will be used to develop new
technologies, including those that uncover
susceptibility to drug therapies. Chief partners
are Wadsworth Center Laboratory and Health
Research, Inc.
- A research center at
Mount Sinai School of Medicine is part of a
national and international multidisciplinary
consortium that is developing a large-scale
project on complex biological systems, with
funding from the National Institute of Health.
Chief partners are SUNY Stony Brook, Cold Spring
Harbor Laboratory, and Columbia University.
Nanotechnology Industry
New York State’s high technology sector is
distinguished by mixed industry-academia
partnerships, access to venture capital, a highly
educated work force, and training resources that
nurture and develop industry leaders. Confirming New
York’s role as a center for future technologies,
Small Times Magazine - a leading business
publication for small-tech companies- reported that
New York State ranks second in the nation in
nanotechnology research and fourth in overall
development of nanotechnology. In addition, the
magazine found that New York was gaining more
nanotech companies and venture capital dollars to
support them.
The Center of Excellence in Nanoelectronics
at the University of Albany has conducted the
state’s most important academic nanotechnology
development efforts. In addition, New York boasts a
host of other world-class nanotechnology research
centers, including Cornell University’s National
Nanotechnology Infrastructure Network and its
Nanobiotechnology Center and Nanoscale Facility, the
Center for Directed Assembly of Nanostructures at
Rensselaer Polytechnic Institute, and the Center for
Electronic Transport in Molecular Nanostructures at
Columbia University.
For more information, please contact Empire State
Development at 1-800-STATE-NY or 1-800 782-8369.
|
|
